Back to Index
Vaccine Advocacy Coalition issues report on Tenofovir prevention Trials
calls for coordinated response to ensure trials continue
Vaccine Advocacy Coalition (AVAC)
March 24, 2005
PDF version (641KB)
If you do not have the free Acrobat reader on your
computer, download it from the Adobe website by clicking
NEW YORK - The AIDS
Vaccine Advocacy Coalition (AVAC) today released a report on issues surrounding
clinical testing of the antiretroviral drug tenofovir as pre-exposure
prophylaxis (PREP) - a possible once-a-day pill for prevention of HIV.
Legitimate ethical concerns raised by some advocates have led to cancellations
and delays in some of the PREP trials. The AVAC report, "Will a Pill a
Day Prevent HIV? Anticipating the Results of the Tenofovir "PREP" Trials,"
examines the issues surrounding the tenofovir trials and makes recommendations
for ensuring that trials are carried out ethically and that provisions
are made for dealing with the results of the trials when they are available.
The report also calls for more concerted coordination and advance planning
to accelerate evaluation, licensing and access to PREP.
"The concerns raised about the trials are serious, and there is a need
for thorough and unbiased investigation," said Mitchell Warren, AVAC Executive
Director. "But all of the concerns raised are solvable. AVAC calls on
researchers, communities and advocates to work together to ensure that
ethical concerns are addressed, solutions are found, and the trials go
The AVAC report calls for a coordinated effort from the World Health Organization,
UNAIDS, the trial sponsors and other organizations to ensure that research
and trials are coordinated and progress in an accelerated fashion, and
that additional research is carried out in an expedited fashion, to ensure
that we will know as soon as possible if tenofovir is a safe and effective
biomedical prevention intervention.
Warren added, "We need as many HIV prevention tools as possible, so research
on vaccines, microbicides and other potential interventions must also
be accelerated whether or not tenofovir proves appropriate for PREP."
"AVAC remains committed to our mission of accelerating development of
an AIDS vaccine, but we are also committed to working in partnership with
other advocates and researchers to advance ethical prevention research
and ensure that the benefits are shared globally."
The report is available online at www.avac.org
and in print on request from email@example.com.
Founded in 1995, the AIDS Vaccine Advocacy Coalition (AVAC) is a non-profit,
community- and consumer-based organization that uses public education,
policy analysis, advocacy and community mobilization to accelerate the
ethical development and global delivery of vaccines against HIV/AIDS.
This special report and AVAC's continuous policy analysis, advocacy, education
and outreach work are made possible by the dedicated labor of AVAC advocates
and support from the Bill & Melinda Gates Foundation, Broadway Cares/Equity
Fights AIDS, the Ford Foundation, the International AIDS Vaccine Initiative,
the Overbrook Foundation, Until There's a Cure Foundation, the WHO-UNAIDS
HIV Vaccine Initiative, and many generous individuals who have become
AVAC Members. AVAC is an IRS-certified 501(c)3 tax exempt organization,
and donations are tax deductible.
Please credit www.kubatana.net if you make use of material from this website.
This work is licensed under a Creative Commons License unless stated otherwise.